/
IPHA
$1.80+$0.01 (+0.56%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$168.1M
94M shares
52-week range
$1.17 – $2.63
43% from low
Exchange
NASDAQ
ADRC
Borrow rate
2.88%
Moderate
Price (6 mo)
Loading chart…
Change$-1.76
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $79.9M | $69.0M | $69.8M | $12.1M | $57.7M | $51.9M | $12.6M | $2.8M |
| Cost of revenue | $69.6M | $45.2M | $49.7M | $47.0M | $51.7M | $56.0M | $52.0M | $0 |
| Gross profit | $10.3M | $23.8M | $20.1M | −$22.3M | $6.0M | $5.6M | $12.6M | $2.8M |
| Gross margin | 12.9% | 34.5% | 28.8% | -184.1% | 10.4% | 10.8% | 100.0% | 100.0% |
| R&D | $69.6M | $1.6M | $49.7M | $47.0M | $51.7M | $56.0M | $52.0M | $43.6M |
| Operating income | $5.1M | −$27.1M | $1.1M | −$47.8M | −$57.4M | −$12.7M | −$51.6M | −$53.4M |
| EBITDA | −$3.3M | −$20.9M | $13.3M | −$43.2M | −$12.3M | −$1.8M | −$46.9M | −$43.6M |
| Net income | $3.0M | −$20.8M | −$64.0M | −$52.8M | −$58.1M | −$7.6M | −$49.5M | −$49.2M |
| Net margin | 3.8% | -30.1% | -91.7% | -436.0% | -100.7% | -14.6% | -392.0% | -1764.5% |
| EPS (diluted) | 0.05 | -0.31 | -0.01 | -0.57 | -0.73 | -0.09 | -0.61 | -0.53 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $31M | $-0.25 | $-0.30–$-0.21 | 2 |
| 2027 | $64M | $0.04 | $0.03–$0.05 | 2 |
| 2028 | $41M | $-0.41 | $-1.50–$-0.02 | 1 |
| 2029 | $190M | $0.34 | $0.02–$1.24 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
www.innate-pharma.com- Employees
- 163
- IPO / List date
- Sep 9, 2015
Held by traders on TradeandTell
No one on the platform currently holds IPHA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in IPHA as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IPHA yet.
